{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:41:26Z","timestamp":1785526886493,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02320-z","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:25:52Z","timestamp":1779506752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond glycemic control: differential effects of empagliflozin and sitagliptin on insulin sensitivity and a shared increase in adropin in type 2 diabetes"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7685-0108","authenticated-orcid":false,"given":"Otbah Salim","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-3957","authenticated-orcid":false,"given":"Golnaz","family":"Azami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-6479","authenticated-orcid":false,"given":"Lotfollah","family":"Saed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-1031","authenticated-orcid":false,"given":"Mohammad Saeed","family":"Hakhamaneshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7508-7452","authenticated-orcid":false,"given":"Heresh","family":"Moridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"2320_CR1","doi-asserted-by":"publisher","first-page":"1143067","DOI":"10.3389\/fendo.2023.1143067","volume":"14","author":"A Mansour","year":"2023","unstructured":"Mansour A, Mousa M, Abdelmannan D, Tay G, Hassoun A, Alsafar H. Microvascular and macrovascular complications of type 2 diabetes mellitus: Exome wide association analyses. Front Endocrinol. 2023;14:1143067.","journal-title":"Front Endocrinol"},{"issue":"3","key":"2320_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ecl.2021.05.013","volume":"50","author":"MG Tinajero","year":"2021","unstructured":"Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metabolism Clin. 2021;50(3):337\u201355.","journal-title":"Endocrinol Metabolism Clin"},{"issue":"9","key":"2320_CR3","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.4239\/wjd.v12.i9.1401","volume":"12","author":"IM El-Kebbi","year":"2021","unstructured":"El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action. World J diabetes. 2021;12(9):1401.","journal-title":"World J diabetes"},{"issue":"11","key":"2320_CR4","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s13300-021-01152-5","volume":"12","author":"ME Khamseh","year":"2021","unstructured":"Khamseh ME, Sepanlou SG, Hashemi-Madani N, Joukar F, Mehrparvar AH, Faramarzi E, et al. Nationwide prevalence of diabetes and prediabetes and associated risk factors among Iranian adults: analysis of data from PERSIAN cohort study. Diabetes Therapy. 2021;12(11):2921\u201338.","journal-title":"Diabetes Therapy"},{"issue":"2","key":"2320_CR5","first-page":"253","volume":"43","author":"A Harihar","year":"2025","unstructured":"Harihar A, Maiya GA, Shetty S, KN S, Bhat S, Kumar S, et al. Profiling of Macrovascular and Microvascular Complications in Young-Onset Type 2 Diabetes: A Scoping Review. Clin Diabetes. 2025;43(2):253\u201361.","journal-title":"Clin Diabetes"},{"issue":"3","key":"2320_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s43152-024-00056-3","volume":"5","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen R. Cellular and molecular mechanisms of insulin resistance. Curr Tissue Microenvironment Rep. 2024;5(3):79\u201390.","journal-title":"Curr Tissue Microenvironment Rep"},{"key":"2320_CR7","doi-asserted-by":"publisher","first-page":"1149239","DOI":"10.3389\/fendo.2023.1149239","volume":"14","author":"X Zhao","year":"2023","unstructured":"Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol. 2023;14:1149239.","journal-title":"Front Endocrinol"},{"issue":"1","key":"2320_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193.","journal-title":"Diabetes Care"},{"issue":"21","key":"2320_CR9","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"R Turner","year":"1999","unstructured":"Turner R, Cull C, Frighi V, Holman R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005\u201312.","journal-title":"JAMA"},{"issue":"8","key":"2320_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2174\/1381612826666201222154616","volume":"27","author":"M Grammatiki","year":"2021","unstructured":"Grammatiki M, Sagar R, Ajjan RA. Metformin: is it still the first line in type 2 diabetes management algorithm? Curr Pharm Design. 2021;27(8):1061\u20137.","journal-title":"Curr Pharm Design"},{"issue":"12","key":"2320_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat reviews Cardiol. 2020;17(12):761\u201372.","journal-title":"Nat reviews Cardiol"},{"issue":"2","key":"2320_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2016","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2016;60(2):215.","journal-title":"Diabetologia"},{"issue":"22","key":"2320_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"2320_CR14","doi-asserted-by":"publisher","first-page":"170196","DOI":"10.1016\/j.peptides.2019.170196","volume":"125","author":"CF Deacon","year":"2020","unstructured":"Deacon CF. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors. Peptides. 2020;125:170196.","journal-title":"Peptides"},{"key":"2320_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3389\/fendo.2019.00389","volume":"10","author":"B Gallwitz","year":"2019","unstructured":"Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol. 2019;10:389.","journal-title":"Front Endocrinol"},{"issue":"4","key":"2320_CR16","doi-asserted-by":"publisher","first-page":"e2981","DOI":"10.1002\/dmrr.2981","volume":"34","author":"A Avogaro","year":"2018","unstructured":"Avogaro A, Delgado E, Lingvay I. When metformin is not enough: pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diab\/Metab Res Rev. 2018;34(4):e2981.","journal-title":"Diab\/Metab Res Rev"},{"key":"2320_CR17","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.molmet.2020.101138","volume":"44","author":"SO Jensen-Cody","year":"2021","unstructured":"Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: Deciphering communication from the liver. Mol metabolism. 2021;44:101138.","journal-title":"Mol metabolism"},{"issue":"6","key":"2320_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.cmet.2008.10.011","volume":"8","author":"KG Kumar","year":"2008","unstructured":"Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of Adropin as a Secreted Factor Linking Dietary Macronutrient Intake with Energy Homeostasis and Lipid Metabolism. Cell Metabol. 2008;8(6):468.","journal-title":"Cell Metabol"},{"issue":"4","key":"2320_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/jcp.22422","volume":"226","author":"NJ Leeper","year":"2011","unstructured":"Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Maegdefessel L, et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol. 2011;226(4):1035\u201343.","journal-title":"J Cell Physiol"},{"key":"2320_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molmet.2017.12.002","volume":"8","author":"S Ghoshal","year":"2018","unstructured":"Ghoshal S, Stevens JR, Billon C, Girardet C, Sitaula S, Leon AS, et al. Adropin: An endocrine link between the biological clock and cholesterol homeostasis. Mol metabolism. 2018;8:51\u201364.","journal-title":"Mol metabolism"},{"key":"2320_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12902-023-01327-0","volume":"23","author":"S Soltani","year":"2023","unstructured":"Soltani S, Beigrezaei S, Malekahmadi M, Clark CC, Abdollahi S. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies. BMC Endocr Disorders. 2023;23:73.","journal-title":"BMC Endocr Disorders"},{"issue":"12","key":"2320_CR22","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/biom14121613","volume":"14","author":"Z Hasanpour-Segherlou","year":"2024","unstructured":"Hasanpour-Segherlou Z, Butler AA, Candelario-Jalil E, Hoh BL. Role of the Unique Secreted Peptide Adropin in Various Physiological and Disease States. Biomolecules. 2024;14(12):1613.","journal-title":"Biomolecules"},{"key":"2320_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12902-022-01233-x","volume":"22","author":"Q Wang","year":"2022","unstructured":"Wang Q, An Y, Zhang L, Zhang Y, Wang G, Liu J. Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes. BMC Endocr Disorders. 2022;22:306.","journal-title":"BMC Endocr Disorders"},{"key":"2320_CR24","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. New York University Lawrence Earlbaum Associates; 1988."},{"issue":"12","key":"2320_CR25","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, et al. Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36(12):4015.","journal-title":"Diabetes Care"},{"issue":"1","key":"2320_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12944-017-0443-4","volume":"16","author":"S-A Cha","year":"2017","unstructured":"Cha S-A, Park Y-M, Yun J-S, Lim T-S, Song K-H, Yoo K-D, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16(1):58.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"2320_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.diabet.2018.01.017","volume":"44","author":"B Mishriky","year":"2018","unstructured":"Mishriky B, Tanenberg R, Sewell K, Cummings D. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018;44(2):112\u201320.","journal-title":"Diabetes Metab"},{"issue":"15","key":"2320_CR28","first-page":"7289","volume":"27","author":"H Zakaraia","year":"2023","unstructured":"Zakaraia H, Salem H, Mostafa M, Ali A, Rabea H. Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial. Eur Rev Med Pharmacol Sci. 2023;27(15):7289\u201398.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"2320_CR29","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"H-U H\u00e4ring","year":"2014","unstructured":"H\u00e4ring H-U, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650\u20139.","journal-title":"Diabetes Care"},{"key":"2320_CR30","doi-asserted-by":"crossref","unstructured":"Cao H, Liu T, Wang L, Ji Q. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: a systematic review and network meta-analysis. 2022;1448\u201357.","DOI":"10.1111\/dom.14702"},{"issue":"1","key":"2320_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12902-022-01168-3","volume":"22","author":"I Ahmed","year":"2022","unstructured":"Ahmed I, Raja UY, Wahab MU, Rehman T, Ishtiaq O, Aamir A, et al. Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. BMC Endocr Disorders. 2022;22(1):247.","journal-title":"BMC Endocr Disorders"},{"issue":"2","key":"2320_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"Suppl 1","key":"2320_CR33","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.4103\/jpbs.jpbs_548_23","volume":"16","author":"H Salankar","year":"2024","unstructured":"Salankar H, Rode S, Arjun C, Joseph R, Deshmane GB, Vijayan RP. Comparative Study on Efficacy of Empagliflozin Versus Sitagliptin, as an Add-on Therapy to Metformin in Type 2 Diabetic Patients. J Pharm Bioallied Sci. 2024;16(Suppl 1):S335\u20138.","journal-title":"J Pharm Bioallied Sci"},{"issue":"1","key":"2320_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-021-01228-3","volume":"20","author":"S Hiruma","year":"2021","unstructured":"Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20(1):32.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2320_CR35","doi-asserted-by":"publisher","first-page":"9149","DOI":"10.1007\/s00210-024-03219-z","volume":"397","author":"SS Talebi","year":"2024","unstructured":"Talebi SS, Rezaie S, Hajmiri MS, Zamanirafe M, Ranjbar A, Moridi H, et al. Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(11):9149\u201365.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"2320_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0977-z","volume":"19","author":"A Fuchigami","year":"2020","unstructured":"Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2320_CR37","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/dom.15006","volume":"25","author":"S Hiruma","year":"2023","unstructured":"Hiruma S, Shigiyama F, Kumashiro N. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early\u2010stage type 2 diabetes with non\u2010alcoholic fatty liver disease: A prospective randomized study. Diabetes Obes Metabolism. 2023;25(6):1576\u201388.","journal-title":"Diabetes Obes Metabolism"},{"issue":"8","key":"2320_CR38","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/dom.12923","volume":"19","author":"CN Joannides","year":"2017","unstructured":"Joannides CN, Mangiafico SP, Waters MF, Lamont BJ, Andrikopoulos S. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity. Diabetes Obes Metabolism. 2017;19(8):1135\u201346.","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"2320_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12902-023-01327-0","volume":"23","author":"S Soltani","year":"2023","unstructured":"Soltani S, Beigrezaei S, Malekahmadi M, Clark CC, Abdollahi S. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies. BMC Endocr disorders. 2023;23(1):73.","journal-title":"BMC Endocr disorders"},{"issue":"1","key":"2320_CR40","doi-asserted-by":"publisher","first-page":"e240117","DOI":"10.1530\/JOE-24-0117","volume":"265","author":"M Skrzypski","year":"2025","unstructured":"Skrzypski M, Wojciechowicz T, Rak A, Kr\u0105\u017cek M, Fiedorowicz J, Strowski MZ, et al. The levels of adropin and its therapeutic potential in diabetes. J Endocrinol. 2025;265(1):e240117.","journal-title":"J Endocrinol"},{"issue":"11 Suppl","key":"2320_CR41","first-page":"S185","volume":"122","author":"F Lovren","year":"2010","unstructured":"Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11 Suppl):S185\u201392.","journal-title":"Circulation"},{"issue":"2","key":"2320_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/biomedicines11020457","volume":"11","author":"AA Berezin","year":"2023","unstructured":"Berezin AA, Obradovic Z, Fushtey IM, Berezina TA, Novikov EV, Schmidbauer L, et al. The impact of SGLT2 inhibitor dapagliflozin on adropin serum levels in men and women with type 2 diabetes mellitus and chronic heart failure. Biomedicines. 2023;11(2):457.","journal-title":"Biomedicines"},{"issue":"1","key":"2320_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11010-020-03686-x","volume":"466","author":"HE Mohamed","year":"2020","unstructured":"Mohamed HE, Asker ME, Keshawy MM, Hasan RA, Mahmoud YK. Inhibition of tumor necrosis factor-\u03b1 enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance. Mol Cell Biochem. 2020;466(1):45\u201354.","journal-title":"Mol Cell Biochem"},{"key":"2320_CR44","doi-asserted-by":"publisher","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","volume":"111","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, et al. The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. Int Immunopharmacol. 2022;111:109080.","journal-title":"Int Immunopharmacol"},{"key":"2320_CR45","doi-asserted-by":"crossref","unstructured":"Telikani Z, Sheikh V, Borzouei S, Salehi I, Amirzargar MA, Alahgholi-Hajibehzad M. Effect of sitagliptin on serum levels of TNF-\u03b1, IL-1\u03b2 and IL-10 in patients with type 2 diabetes mellitus. Koomesh. 22(1):71\u20137.","DOI":"10.29252\/koomesh.22.1.71"},{"issue":"2","key":"2320_CR46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Investig. 2014;124(2):499.","journal-title":"J Clin Investig"},{"issue":"7","key":"2320_CR47","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115\u201322.","journal-title":"Diabetes Care"},{"issue":"2","key":"2320_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/jdi.12915","volume":"10","author":"M Fukuda","year":"2019","unstructured":"Fukuda M, Doi K, Sugawara M, Mochizuki K. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia. J diabetes Invest. 2019;10(2):383\u201391.","journal-title":"J diabetes Invest"},{"issue":"6","key":"2320_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/met.2022.0004","volume":"20","author":"R Premji","year":"2022","unstructured":"Premji R, Nylen ES, Naser N, Gandhi S, Burman KD, Sen S. Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome. Metab Syndr Relat Disord. 2022;20(6):321\u20138.","journal-title":"Metab Syndr Relat Disord"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02320-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02320-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02320-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:05:39Z","timestamp":1785521139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02320-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02320-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol and statistical analysis plan were reviewed and approved by the Research Ethics Committee of Kurdistan University of Medical Sciences, Sanandaj, Iran (Ethics approval code: IR.MUK.REC.1403.323). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional research committee and adhered to the principles of the Declaration of Helsinki. Written and verbal informed consent was obtained from all participants prior to enrollment, and the consent procedure was formally approved by the Ethics Committee. Participants received a detailed explanation of the study\u2019s purpose, procedures, and potential risks, and all questions were addressed by the research team. Participation was entirely voluntary, with the right to withdraw at any stage without penalty. Confidentiality and anonymity were rigorously maintained: personal identifiers were removed from the dataset, data were stored securely with access restricted to the research team, and results are reported in aggregate form to ensure that no individual participant can be identified.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors utilized Ludwig.Guru, an AI-based linguistic search and editing tool, to enhance the clarity and precision of the language. This resource assisted in refining the grammar and academic style of the text.","order":2,"name":"Ethics","label":"Use of AI and AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this manuscript does not contain any individual person\u2019s data in any form (including images, videos, or case details).","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"211"}}